DEXA scans on tirzepatide: what body composition actually shows at 6 months

The trial averages on tirzepatide and weight composition tell one story. Patient DEXA scans across 6-12 months tell a more textured one. The scale moves the same; what's underneath it varies more than people realize.

For context: SURMOUNT-1 reported that approximately 75% of weight loss on tirzepatide was fat mass and approximately 25% was lean mass. This is significantly better than the typical caloric-deficit-only outcome (where lean mass loss can be 35-40% of total weight loss) but worse than what's achievable with a structured resistance training program at energy balance.

If you scan yourself, here's what you'll likely see at the major checkpoints.

Baseline scan (week 0)

Scan before the first injection if you can. The reason is that the first 2-4 weeks of weight loss includes meaningful water mass and intestinal content shifts that don't represent fat or lean tissue change. Without a baseline, the 3-month scan doesn't have a clean reference point.

The numbers worth recording: total body fat percentage, total lean mass (kg), visceral adipose tissue (cm³ or graded scale depending on machine), bone mineral density (informational, not actionable in the short term).

3-month scan

Most patients have lost 8-15% of starting body weight by month three on a standard ramp. The DEXA breakdown most people see:

• Fat mass loss: 70-80% of total weight lost
• Lean mass loss: 15-25% of total weight lost
• Water/intestinal content: roughly 5-10% (transient)

The lean mass loss number is the one that matters for the long-term trajectory. If yours is closer to 25-30% of total weight lost in the first three months, that's a signal to recalibrate. The two highest-leverage interventions:

• Audit protein intake. Most "high lean mass loss" patients are eating less than 1.4g/kg of target body weight in protein.
• Audit resistance training. If you're not lifting at all, the lean mass loss compounds.

If your three-month scan shows fat-mass-dominant loss (less than 15% of weight from lean), the protocol is working. Don't change anything; keep going.

6-month scan

The interesting checkpoint. By month six, most patients have lost 15-22% of starting body weight on full ramp tirzepatide. The DEXA profile typically shows:

• Fat mass loss continuing at high efficiency
• Lean mass loss slowing or stabilizing (your body has adapted)
• Visceral adipose tissue dropping disproportionately (often the most dramatic single change)
• Bone mineral density stable or very slightly declining (worth monitoring but rarely actionable)

The visceral fat reduction is often the most clinically meaningful number on the 6-month scan. Visceral adiposity correlates with cardiometabolic risk more strongly than total body fat percentage, and tirzepatide preferentially mobilizes visceral fat earlier than peripheral fat. This is why people who don't look dramatically different at month 6 often have dramatically better lab markers.

If your 6-month scan shows continued lean mass loss at the same rate as the first 3 months, this is the time to seriously revisit the training and protein protocol. The body composition pattern at month 6 sets the trajectory for month 12.

12-month scan

Most patients have stabilized at 18-25% total weight loss by month twelve. The DEXA usually shows:

• Fat mass continuing to decline modestly
• Lean mass either stable or recovering slightly (people who lifted consistently)
• Visceral fat substantially reduced from baseline
• Body fat percentage often similar or slightly lower than baseline despite total mass being much lower (because lean mass dropped less in absolute terms)

The 12-month scan is where the real-world success vs trial-average differentiation shows up. Patients who hit higher protein targets and trained consistently often have better body composition at 12 months than the trial averages would predict. Patients who didn't sometimes have similar weight loss but worse composition.

What the scale misses

A few patterns DEXA reveals that the scale alone doesn't:

The "stuck weight" with continued composition improvement. Some patients hit a weight plateau at month 4-6 but continue to improve body composition for another 2-3 months without the scale moving. This is real recomposition (lean mass increasing as fat mass decreases) and is genuinely good even though the scale is uncooperative.

The "looks the same" with major visceral reduction. Visceral fat reduction often precedes visible peripheral fat reduction. Someone who feels they've lost weight but don't look different may have lost most of their loss from visceral compartments where it's metabolically meaningful but visually subtle.

The "lost too much lean" with rebound risk. Patients who lose 30%+ of their weight from lean mass have a worse rebound trajectory if they stop the drug. The body re-establishes its set point partly based on lean mass; lower lean mass at the new weight predicts faster regain.

Whether to actually scan

DEXA isn't free and isn't always available. The decision depends on whether the additional information would change what you do.

Reasons to scan:

• You're concerned about muscle loss and want a measurable answer
• You're seeing weight plateau but feel composition is changing
• You want to track visceral fat reduction over time

Reasons it's optional:

• The trial averages are reassuring enough for most patients
• Body fat scales (the at-home electrical impedance ones) are unreliable but free
• A tape measure (waist circumference) captures most of the actionable information about visceral adiposity for free

The cost is roughly $80-200 in the US, $40-100 in most Asian markets. A scan at baseline, 6 months, and 12 months runs $200-600 total, which is reasonable for someone making serious changes. Quarterly scans are mostly overkill.

The practical version

If you scan once: do it at six months. The data is most actionable then.

If you scan twice: baseline plus six months. The baseline gives the comparison; six months is the inflection point.

If you scan three times: baseline, six months, twelve months. The twelve-month scan is where you decide whether to dose-down to maintenance.

If your numbers at any point look meaningfully off the trial averages and you don't know why, that's the moment to talk to a sports physician or registered dietitian, not to push the dose higher hoping it sorts itself out.